Hilleman Laboratories is a global vaccine research & development organization focused on making affordable vaccines using innovation to address gaps that exist in low resource settings. Hilleman Labs acts as a catalyst in bridging the gap between academic research and product development by targeting novel vaccines and increasing the efficiency of existing vaccines.Know More
Developing vaccines for global health
Hilleman Laboratories is committed to developing high impact, affordable vaccines for people in developing countries in an innovative and sustainable manner.
Hilleman Laboratories announces creation of new Strategic Advisory Committe
January 18th, 2019
Hilleman Laboratories announces creation of new Strategic Advisory CommitteKnow More
Cheap, painless vaccine patches to be available in India in a couple of years
December 11th, 2018
Cheap, painless vaccine patches to be available in India in a couple of yearsKnow More
Hilleman Labs announces publication of original research on Heat Stable Rotavirus Vaccines
September 11th, 2018
Hilleman Laboratories today announced the publication of original research as well as expert commentKnow More
Hilleman Laboratories partners with innovative Future Vaccine Manufacturing Hub
January 09th, 2018
Hilleman Laboratories to collaborate with Imperial College London, Engineering and Physical SciencesKnow More
Hilleman Labs successfully completes Phase I/II Clinical Trial of its Heat Stable Rotavirus Vaccine (HSRV)
October 12th, 2017
Making headway towards providing the developing nations an affordable and easy-to-use Heat Stable RoKnow More
We have established modern research and development laboratories to play a crucial role in the process of health development in India and other under-developed countries.
We are collaborating with the global public health community on the development of optimized vaccines with target product profiles relevant to low income countries.
The World Health Organization estimates that 600,000 children under the age of 5 die annually due to rotavirus diarrhoea and another two million are hospitalized.